Skip to main content
SpringerLink
Log in
Book cover

Disease Recurrence After Liver Transplantation pp 1–11Cite as

Overview: Disease Recurrence After Liver Transplantation

  • Chapter

  • 685 Accesses

Abstract

The expected 1-year and 5-year patient survival rates after liver transplantation (LT) are 85–95 % and 75–85 %, respectively. The common causes of long-term mortality after LT are recurrence of primary liver disease or cancer for which LT was performed, cardiovascular events, de novo malignancy, and renal failure. In this book, we focus on disease recurrence after LT and critically analyze our current understanding of the incidence and diagnosis of disease recurrence, natural history, treatment options, and quality of life. Although disease recurrence is common after LT, only few conditions appear to have a major impact on graft survival. De novo diseases specific to LT recipients may also appear after LT in both adults and children. Early recognition of recurrent disease and de novo conditions will improve the survival of LT recipients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Thuluvath PJ, Guidinger MK, Fung J, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10:1003–19.

    Article  CAS  PubMed  Google Scholar 

  2. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation. 2000;69:781–9.

    Article  CAS  PubMed  Google Scholar 

  3. Asfar S, Metrakos P, Fryer J, et al. An analysis of late deaths after liver transplantation. Transplantation. 1996;61:1377–81.

    Article  CAS  PubMed  Google Scholar 

  4. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001;7:811–5.

    Article  CAS  PubMed  Google Scholar 

  5. Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation. 2002;73:901–6.

    Article  PubMed  Google Scholar 

  6. Abbasoglu O, Levy MF, Brkic BB, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation. 1997;64:1801–7.

    Article  CAS  PubMed  Google Scholar 

  7. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology. 2002;35:105–9.

    Article  PubMed  Google Scholar 

  8. John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology. 2001;34:889–95.

    Article  CAS  PubMed  Google Scholar 

  9. Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation. 2002;74:1007–12.

    Article  CAS  PubMed  Google Scholar 

  10. John PR, Thuluvath PJ. Outcome of patients with new onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl. 2002;8:708–13.

    Article  PubMed  Google Scholar 

  11. Thuluvath PJ. When is diabetes mellitus a relative or absolute contraindication to liver transplantation? Liver Transpl. 2005;11:S25–9.

    Article  PubMed  Google Scholar 

  12. Thuluvath PJ, Yoo HY, Thompson RE. A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics. Liver Transpl. 2003;9:527–32.

    Article  PubMed  Google Scholar 

  13. Guckelberger O, Byram A, Klupp J, et al. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int. 2005;18:967–74.

    Article  PubMed  Google Scholar 

  14. Segev DL, Maley WR, Simpkins CE, et al. Minimizing risk associated with elderly liver donor by matching to preferred recipients. Hepatology. 2007;46:1907–18.

    Article  PubMed  Google Scholar 

  15. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137(5):1680–6.

    Article  PubMed Central  PubMed  Google Scholar 

  16. O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14(1):104.

    Article  PubMed  Google Scholar 

  17. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology. 1991;13(4):619–26.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528–35.

    Article  PubMed  Google Scholar 

  19. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10(8):968–74.

    Article  PubMed  Google Scholar 

  20. Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10(8):1823–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology. 2000;32:852–8.

    Article  CAS  PubMed  Google Scholar 

  22. Forman LM, Lewis J, Berlin J, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–96.

    Article  PubMed  Google Scholar 

  23. García-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–7.

    Article  PubMed  Google Scholar 

  24. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28–34.

    Article  PubMed  Google Scholar 

  25. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.

    Article  CAS  PubMed  Google Scholar 

  26. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–6.

    Article  CAS  PubMed  Google Scholar 

  27. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16(11):1228–35.

    Article  PubMed  Google Scholar 

  28. Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78–88.

    Article  PubMed  Google Scholar 

  29. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108–17.

    Article  CAS  PubMed  Google Scholar 

  30. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. American Association for the Study of Liver Diseases (AASLD) liver meeting, Boston, 7–12 Nov 2014, Abstract 8; 2014.

    Google Scholar 

  31. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13(6):1601–5.

    Article  CAS  PubMed  Google Scholar 

  32. Fontano R, Bahirwani R, Reddy R, et al. High efficacy and favorable safety profile of daclatasvir based all oral antiviral therapy in liver transplant recipients with severe recurrent HCV. American Association for the Study of Liver Diseases (AASLD) liver meeting. Boston, 7–12 Nov 2014, Abstract LB-22; 2014.

    Google Scholar 

  33. Neuberger J, Portmann B, Macdougall BR, et al. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med. 1982;306:1–4.

    Article  CAS  PubMed  Google Scholar 

  34. Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007;13:1236–45.

    Article  PubMed  Google Scholar 

  35. Abu-Elmagd K, Demetris J, Rakela J, et al. Transplantation for primary biliary cirrhosis: disease recurrence and outcome in 421 patients. Hepatology. 1997;26:176A.

    Article  Google Scholar 

  36. Liermann-Garcia RF, Evangelista-Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology. 2001;33:22–7.

    Article  CAS  PubMed  Google Scholar 

  37. Sanchez EQ, Levy MF, Goldstein RM, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation. 2003;76:1583–6.

    Article  PubMed  Google Scholar 

  38. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years. Gastroenterology. 2002;123:1044–51.

    Article  PubMed  Google Scholar 

  39. Sylvestre PB, Batts KP, Burgart LJ, et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl. 2003;9:1086–93.

    Article  PubMed  Google Scholar 

  40. Hubscher S, Elias E, Buckels J, et al. Primary biliary cirrhosis: histological evidence of disease recurrence after liver transplantation. J Hepatol. 1993;18:173–84.

    Article  CAS  PubMed  Google Scholar 

  41. Sebagh M, Farges O, Dubel L, et al. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation. 1998;65:1328–33.

    Article  CAS  PubMed  Google Scholar 

  42. Abraham SC, Poterucha JJ, Rosen CB, et al. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol. 2008;32:965–73.

    Article  PubMed  Google Scholar 

  43. Klein R, Huezenga JR, Gips CH, et al. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol. 1994;20:181–9.

    Article  CAS  PubMed  Google Scholar 

  44. Levtisky J, Hart J, Cohen SM, et al. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl. 2003;9:733–6.

    Article  Google Scholar 

  45. Manousou P, Arvanti V, Tsochatzis E, et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and HLA locus disparity. Liver Transpl. 2010;16:64–73.

    Article  PubMed  Google Scholar 

  46. Neuberger J, Gunson B, Hubscher S, et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004;10:488–91.

    Article  PubMed  Google Scholar 

  47. Guy JE, Qian P, Lowell JA, et al. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 2005;11:1252–7.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation—when non-self becomes self. Hepatology. 2000;32(4):868–70.

    Article  CAS  PubMed  Google Scholar 

  49. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology. 2000;32(2):185–92.

    Article  CAS  PubMed  Google Scholar 

  50. Duclos-Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut. 2003;52(6):893–7.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30(1):131–41.

    Article  CAS  PubMed  Google Scholar 

  52. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology. 2000;32(4):693–700.

    Article  CAS  PubMed  Google Scholar 

  53. Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl. 2001;7(4):285–91.

    Article  CAS  PubMed  Google Scholar 

  54. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351(9100):409–13.

    Article  CAS  PubMed  Google Scholar 

  55. Castillo-Rama M, Sebagh M, Sasatomi E, et al. “Plasma cell hepatitis” in liver allografts: identification and characterization of an IgG4 rich cohort. Am J Transplant. 2013;13:2966–77.

    Article  CAS  PubMed  Google Scholar 

  56. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002;35(2):349–56.

    Article  CAS  PubMed  Google Scholar 

  57. Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl. 2008;14(2):159–72.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Shawcross DL, O’Grady JG. The 6-month abstinence rule in liver transplantation. Lancet. 2010;376:216–7.

    Article  PubMed  Google Scholar 

  59. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl. 2006;12:813–20.

    Article  PubMed  Google Scholar 

  60. Beresford TP, Everson GT. Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse—but where are the data? Liver Transpl. 2000;6:777–8.

    Article  CAS  PubMed  Google Scholar 

  61. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790–800.

    Article  CAS  PubMed  Google Scholar 

  62. Rice JP, Eickhoff J, Agni R, et al. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013;19(12):1377–86.

    Article  PubMed  Google Scholar 

  63. Grąt M, Lewandowski Z, Grąt K, et al. Negative outcomes after liver transplantation in patients with alcoholic liver disease beyond the fifth post-transplant year. Clin Transplant. 2014;28(10):1112–20.

    Article  PubMed  Google Scholar 

  64. Iruzubieta P, Crespo J, Fábrega E. Long-term survival after liver transplantation for alcoholic liver disease. World J Gastroenterol. 2013;19(48):9198–208.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Coordes A, Albers AE, Lenarz M, et al. Incidence and long-term survival of patients with de-novo head and neck carcinoma after liver transplantation. Head Neck. 2014 Dec 18. doi:10.1002/hed.23943. [Epub ahead of print].

    Google Scholar 

  66. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006;44:746–64.

    Article  PubMed  Google Scholar 

  67. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813–24.

    Article  PubMed  Google Scholar 

  68. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2002;8:575–81.

    Article  PubMed  Google Scholar 

  69. Sheng R, Campbell WL, Zajko AB, et al. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol. 1996;166:1109–13.

    Article  CAS  PubMed  Google Scholar 

  70. Demetris AJ. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl. 2006;12:S68–72.

    Article  PubMed  Google Scholar 

  71. Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation. 1998;66:1300–6.

    Article  CAS  PubMed  Google Scholar 

  72. Lerut J, Demetris AJ, Stieber AC, et al. Intrahepatic bile duct strictures after human orthotopic liver transplantation. Recurrence of primary sclerosing cholangitis or unusual presentation of allograft rejection? Transpl Int. 1988;1:127–30.

    PubMed Central  CAS  PubMed  Google Scholar 

  73. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol. 2004;99:538–42.

    Article  PubMed  Google Scholar 

  74. Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78:637–43.

    Article  CAS  PubMed  Google Scholar 

  75. Wilczek HE, Larsson M, Ericzon BG, et al. Long term data from Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18 Suppl 1:193–5.

    Article  PubMed  Google Scholar 

  76. Shimojima Y, Morita H, Kobayashi S, et al. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol. 2008;255:1220–5.

    Article  PubMed  Google Scholar 

  77. Tashima K, Ando Y, Terazaki H, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloid polyneuropathy patients. J Neurol Sci. 1999;171:19–23.

    Article  CAS  PubMed  Google Scholar 

  78. Okamoto S, Yamashita T, Ando Y, et al. Evaluation of myocardial changes in familial amyloid polyneuropathy after liver transplantation. Intern Med. 2008;47:2133–7.

    Article  PubMed  Google Scholar 

  79. Ohya Y, Yamashita T, Tasaki M, et al. Manifestation of tranthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today. 2011;41:1211–8.

    Article  PubMed  Google Scholar 

  80. Caravalho A, Rocha A, Lobato L. Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21:282–92.

    Article  Google Scholar 

  81. Yu L, Ioannou GN. Gastroenterology. 2007;33:489–95.

    Article  Google Scholar 

  82. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.

    Article  PubMed  Google Scholar 

  83. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant. 2004;4:686–93.

    Article  PubMed  Google Scholar 

  84. Albeldawi M, Aggarwal A, Madhwal S, et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 2012;18(3):370–5.

    Article  PubMed  Google Scholar 

  85. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  CAS  PubMed  Google Scholar 

  86. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.

    Article  CAS  PubMed  Google Scholar 

  87. Yoo HY, Patt CH, Geschwind JF, et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol. 2003;21:4329–35.

    Article  PubMed  Google Scholar 

  88. Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl. 2009;15:859–68.

    Article  PubMed  Google Scholar 

  89. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17:S44–57.

    Article  PubMed  Google Scholar 

  90. Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl. 2006;12:1504–11.

    Article  PubMed  Google Scholar 

  91. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002;2(8):774–9.

    Article  PubMed  Google Scholar 

  92. Senzer NN, Stone MJ, Klintmalm GB, et al. Adjuvant radiochemotherapy following orthotopic liver transplantation for bile duct cancer. Transplantation. 1990;50(6):1045–7.

    Article  CAS  PubMed  Google Scholar 

  93. Salgia RJ, Singal AG, Fu S, et al. Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000. Dig Dis Sci. 2014;59(5):1048–54.

    Article  PubMed  Google Scholar 

  94. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. 2000;69(8):1633–7.

    Article  CAS  PubMed  Google Scholar 

  95. Hassoun Z, Gores GJ, Rosen CB, et al. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2002;11(4):909–21.

    Article  PubMed  Google Scholar 

  96. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98.

    Article  PubMed  Google Scholar 

  97. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2006;82(12):1703–7.

    Article  CAS  PubMed  Google Scholar 

  98. Hong J, Petrowsky H, Kaldas FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg. 2011;212(4):514–20; discussion 520–1.

    Article  PubMed  Google Scholar 

  99. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg. 1996;2:52–9.

    Article  CAS  PubMed  Google Scholar 

  100. Benten D, Sterneck M, Panse J, et al. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl. 2008;14:789–98.

    Article  PubMed  Google Scholar 

  101. Jain A, Fiaz O, Sheikh B, et al. Recurrent nonhepatic and de novo malignancies after liver transplantation. Transplantation. 2009;88:706–10.

    Article  PubMed  Google Scholar 

  102. Le Treut YP, Gregoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807–15.

    Article  PubMed  Google Scholar 

  103. Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001;7:S109–18.

    Article  CAS  PubMed  Google Scholar 

  104. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg. 2000;232:490–500.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  105. Oo YH, Gunson BK, Lancashire RJ, et al. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation. 2005;80:759–64.

    Article  PubMed  Google Scholar 

  106. Sint Nicolaas J, de Jonge V, Steyerberg EW, et al. Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am J Transplant. 2010;10:868–76.

    Article  CAS  PubMed  Google Scholar 

  107. Higashi H, Yanaga K, Marsh JW, et al. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology. 1990;11:477–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  108. McAteer JP, Goldin AB, Healey PJ, et al. Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr Transplant. 2013;17(8):744–50.

    Article  PubMed  Google Scholar 

  109. Scalori A, Heneghan M, Hadzic N, et al. Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis: a 13-year follow up study. Hepatology. 2007;46(Suppl):555A.

    Google Scholar 

  110. Maggiore G, Sciveres M, Fabre M, et al. Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. J Pediatr. 2011;159(1):127–32.e1; Epub 2011/02/26.

    Article  PubMed  Google Scholar 

  111. Raj S, Stephen T, Debski RF. Giant cell hepatitis with autoimmune hemolytic anemia: a case report and review of pediatric literature. Clin Pediatr. 2011;50(4):357–9; Epub 2011/03/26.

    Article  Google Scholar 

  112. Jara P, Hierro L, Martinez-Fernandez P, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med. 2009;361(14):1359–67.

    Article  CAS  PubMed  Google Scholar 

  113. Tome S, Wells JT, Said A, et al. Quality of life after liver transplantation: a systematic review. J Hepatol. 2008;48(4):567–77.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Digestive Health and Liver Disease, Mercy Medical Center & University of Maryland School of Medicine, Baltimore, MD, 21202, USA

    Paul J. Thuluvath MD, AGAF, FACG, FAASLD, FRCP

Authors
  1. Paul J. Thuluvath MD, AGAF, FACG, FAASLD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul J. Thuluvath MD, AGAF, FACG, FAASLD, FRCP .

Editor information

Editors and Affiliations

  1. Institute for Digestive Health & Liver Disease, Mercy Medical Center & University of Maryland School of Medicine, Baltimore, Maryland, USA

    Paul J. Thuluvath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Thuluvath, P.J. (2016). Overview: Disease Recurrence After Liver Transplantation. In: Thuluvath, P. (eds) Disease Recurrence After Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2947-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2947-4_1

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2946-7

  • Online ISBN: 978-1-4939-2947-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation